Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
Sonia Ndeupen, Zhen Qin, Sonya Jacobsen, et al.
iScience (2021) Vol. 24, Iss. 12, pp. 103479-103479
Open Access | Times Cited: 379

Showing 26-50 of 379 citing articles:

Strategies to reduce the risks of mRNA drug and vaccine toxicity
Dimitrios Bitounis, Eric Jacquinet, Maximillian A. Rogers, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 281-300
Closed Access | Times Cited: 52
Unsaturated, Trialkyl Ionizable Lipids are Versatile Lipid‐Nanoparticle Components for Therapeutic and Vaccine Applications
Kieu Lam, Ada Leung, Alan Martin, et al.
Advanced Materials (2023), pp. 2209624-2209624
Open Access | Times Cited: 51
‘Spikeopathy’: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA
Peter Parry, Astrid Lefringhausen, Conny Turni, et al.
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2287-2287
Open Access | Times Cited: 51
Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine–associated myocarditis
Anis Barmada, Jon Klein, Anjali Ramaswamy, et al.
Science Immunology (2023) Vol. 8, Iss. 83
Open Access | Times Cited: 48
mRNA vaccines: The future of prevention of viral infections?
Piotr Rzymski, Agnieszka Szuster−Ciesielska, Tomasz Dzieciątkowski, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 2
Closed Access | Times Cited: 46
Evolution of nanomedicine formulations for targeted delivery and controlled release
Sanyogitta Puri, Mariarosa Mazza, Gourgopal Roy, et al.
Advanced Drug Delivery Reviews (2023) Vol. 200, pp. 114962-114962
Closed Access | Times Cited: 41
The immunostimulatory nature of mRNA lipid nanoparticles
Preeti Sharma, Daniek Hoorn, Anjaiah Aitha, et al.
Advanced Drug Delivery Reviews (2024) Vol. 205, pp. 115175-115175
Open Access | Times Cited: 34
The Promise and Potential of Metal–Organic Frameworks and Covalent Organic Frameworks in Vaccine Nanotechnology
Yalini H. Wijesundara, Thomas S. Howlett, Sneha Kumari, et al.
Chemical Reviews (2024) Vol. 124, Iss. 6, pp. 3013-3036
Closed Access | Times Cited: 23
A comprehensive comparison of DNA and RNA vaccines
Chunxi Wang, Fan Yuan
Advanced Drug Delivery Reviews (2024) Vol. 210, pp. 115340-115340
Closed Access | Times Cited: 16
Mucosal immune response in biology, disease prevention and treatment
Xiaoxue Zhou, Yuchen Wu, Zhipeng Zhu, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Exacerbation of immune thrombocytopenia following COVID‐19 vaccination
David J. Kuter
British Journal of Haematology (2021) Vol. 195, Iss. 3, pp. 365-370
Open Access | Times Cited: 87
Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model
Can Li, Yanxia Chen, Yan Zhao, et al.
Clinical Infectious Diseases (2021) Vol. 74, Iss. 11, pp. 1933-1950
Open Access | Times Cited: 84
Autoimmune phenomena following SARS-CoV-2 vaccination
Yuval Ishay, Ariel Kenig, Tehila Tsemach-Toren, et al.
International Immunopharmacology (2021) Vol. 99, pp. 107970-107970
Open Access | Times Cited: 79
Future considerations for the mRNA-lipid nanoparticle vaccine platform
Botond Z. Igyártó, Sonya Jacobsen, Sonia Ndeupen
Current Opinion in Virology (2021) Vol. 48, pp. 65-72
Open Access | Times Cited: 78
Self-assembled polymeric micelle as a novel mRNA delivery carrier
Jin Ren, Yiming Cao, Lei Li, et al.
Journal of Controlled Release (2021) Vol. 338, pp. 537-547
Open Access | Times Cited: 59
Unadjuvanted intranasal spike vaccine booster elicits robust protective mucosal immunity against sarbecoviruses
Tianyang Mao, Benjamin Israelow, Alexandra Suberi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 58
Lipid nanoparticles for mRNA delivery
Hiroki Tanaka, Yu Sakurai, Hidetaka Akita
Drug Delivery System (2022) Vol. 37, Iss. 3, pp. 237-246
Open Access | Times Cited: 56
An Integrated Polymeric mRNA Vaccine without Inflammation Side Effects for Cellular Immunity Mediated Cancer Therapy
Pei Huang, Lingsheng Jiang, Hui Pan, et al.
Advanced Materials (2022) Vol. 35, Iss. 3
Closed Access | Times Cited: 54
Adverse effects of COVID-19 vaccines and measures to prevent them
Kenji Yamamoto
Virology Journal (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 51
Apparent risks of postural orthostatic tachycardia syndrome diagnoses after COVID-19 vaccination and SARS-Cov-2 Infection
Alan C. Kwan, Joseph E. Ebinger, Janet Wei, et al.
Nature Cardiovascular Research (2022) Vol. 1, Iss. 12, pp. 1187-1194
Open Access | Times Cited: 50
Route of self-amplifying mRNA vaccination modulates the establishment of pulmonary resident memory CD8 and CD4 T cells
Marco Künzli, Stephen O’Flanagan, Madeleine LaRue, et al.
Science Immunology (2022) Vol. 7, Iss. 78
Open Access | Times Cited: 49
Pro-inflammatory concerns with lipid nanoparticles
S. Moein Moghimi, Dmitri Simberg
Molecular Therapy (2022) Vol. 30, Iss. 6, pp. 2109-2110
Open Access | Times Cited: 45
Increased Interleukin 18-Dependent Immune Responses Are Associated With Myopericarditis After COVID-19 mRNA Vaccination
Taejoon Won, Nisha A. Gilotra, Megan Kay Wood, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 42
Design and lyophilization of lipid nanoparticles for mRNA vaccine and its robust immune response in mice and nonhuman primates
Yuta Suzuki, Takayuki Miyazaki, Hiroki Muto, et al.
Molecular Therapy — Nucleic Acids (2022) Vol. 30, pp. 226-240
Open Access | Times Cited: 42
Current Evidence in SARS-CoV-2 mRNA Vaccines and Post-Vaccination Adverse Reports: Knowns and Unknowns
Dimitra S. Mouliou, Efthimios Dardiotis
Diagnostics (2022) Vol. 12, Iss. 7, pp. 1555-1555
Open Access | Times Cited: 39

Scroll to top